Wall Street Stock Market & Finance report, prediction for the future: You'll find the Entasis Therapeutics Holdings share forecasts, stock quote and buy / sell signals below.According to present data Entasis Therapeutics Holdings's ETTX shares and potentially its … Get the hottest stocks to trade every day before the market opens 100% free. Its products candidate includes Zoliflodacin, ETX0282CPDP, and NBP program. The summary for ENTASIS THERAPEUTICS HLDGS INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Learn how Entasis is working to keep bacterial resistance at bay and make meaningful change. Real-time quotes, advanced visualizations, backtesting, and much more. The average Entasis Therapeutics Holdings stock price prediction forecasts a potential downside of N/A from the current ETTX share price of $3.04. stock was originally listed at a price of $10.66 in Sep 26, 2018. Entasis Therapeutics Holdings. Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). The summary for ENTASIS THERAPEUTICS HLDGS INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. View the real-time ETTX price chart on Robinhood and decide if you want to buy or sell commission-free. Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. Taking a look at stock … Entasis Therapeutics General Information Description. WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused … Post-Market 0.01 (0.34%) Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. — Ruben Tommasi, Chief Scientific Officer ©2021 Entasis Therapeutics Inc. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Entasis Therapeutics against related stocks people have also bought. Find real-time ETTX - Entasis Therapeutics Holdings Inc stock quotes, company profile, news and forecasts from CNN Business. Entasis Therapeutics Awarded Contract from National Institutes of Health. Entasis Therapeutics Holdings Inc. [NASDAQ: ETTX] price surged by 5.75 percent to reach at $0.1. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. TipRanks. How has Entasis Therapeutics' stock price been impacted by Coronavirus? Entasis Therapeutics Holdings Inc. [NASDAQ: ETTX] price surged by 5.75 percent to reach at $0.1. Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. ETTX: Get the latest Entasis Therapeutics stock price and detailed information including ETTX news, historical charts and realtime prices. View the real-time ETTX price chart on Robinhood and decide if you want to buy or sell commission-free. The average Entasis Therapeutics Holdings stock price prediction forecasts a potential downside of N/A from the current ETTX share price of $3.04. View Entasis Therapeutics Holdings Inc. ETTX investment & stock information. Click here now. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sc… Entasis Therapeutics Holdings Inc stock is down -63.28% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives ETTX stock a score of 32 out of a possible 100.. That rank is primarily influenced by a long-term technical score of 2. Entasis Therapeutics Holdings (ETTX) stock price prediction is 1.676019 USD. View real-time stock prices and stock quotes for a full financial overview. 2021 Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) shares, rose in value on Friday, Feb 05, with the stock price up by 5.79% to the previous day’s close as strong demand from buyers drove the stock to $3.29. Media Contact Kirsten Thomas The Ruth Group (508) 280-6592 kthomas@theruthgroup.com. © It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. We have assembled a world-class team with a global calling to work on these life-saving, long lasting antibacterial therapies. The move came on … Companies that used to be publicly owned tend to have lower insider ownership. Entasis Therapeutics Stock Price . Entasis Therapeutics Holdings's share price could stay at $6.33 by Sep 9, 2021. Entasis Therapeutics Holdings. Free trial. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. Entasis Therapeutics Holdings Inc. Common Stock (ETTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Entasis Therapeutics Awarded Contract from National Institutes of Health. Stock analysis for Entasis Therapeutics Holdings Inc (ETTX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Rewards. The high price target for ETTX is $9.00 and the low price target for ETTX is $5.00. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. If you had invested in Entasis Therapeutics Holdings stock at $10.66, your return over the last 2 years would have been -73.45%, for an annualized return of -48.48%. Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4% Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. GlobeNewswire. A high-level overview of Entasis Therapeutics Holdings Inc. (ETTX) stock. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. GlobeNewswire 49d 40 Stocks Moving in Wednesday's Pre-Market Session 8 Wall Street analysts have issued ratings and price targets for Entasis Therapeutics in the last 12 months. Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. The stock's open price was 2.52. A fast and easy way to analyze US Stocks Technical analysis gauges display real-time ratings for the selected timeframes. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. for only. Follow ETTX. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference, We Think Entasis Therapeutics Holdings (NASDAQ:ETTX) Needs To Drive Business Growth Carefully, Entasis Therapeutics to Participate in A.G.P.s Virtual Healthcare Symposium, Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update, Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week, Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences, Entasis Therapeutics Announces $25 Million Private Placement, Entasis Therapeutics Reports Second Quarter 2020 Financial Results and Business Update, Entasis Therapeutics to Participate in Upcoming Healthcare Conferences, Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%, Entasis Therapeutics Awarded Contract from National Institutes of Health, Analysts: These 3 Penny Stocks May Very Well Be Worth the Risk, Entasis Therapeutics to Participate in the BMO 2020 Prescriptions for Success Healthcare Conference, Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva, Analysts Suggest Buying These 2 Falling Knives, Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update, Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva, Earnings Release: Here's Why Analysts Cut Their Entasis Therapeutics Holdings Inc. Price Target To US$14.50, Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update, Introducing Entasis Therapeutics Holdings (NASDAQ:ETTX), The Stock That Dropped 16% In The Last Year. On average, Wall Street analysts predict that . Big Cap Pro. Click here now. It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by … Results are available at a … Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Get the latest Entasis Therapeutics Holdings I (ETTX) stock news and headlines to help you in your trading and investing decisions. Click here now. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts. Find the latest Entasis Therapeutics Holdings I (ETTX) stock quote, history, news and other vital information to help you with your stock trading and investing. The move came on … Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The Entasis Therapeutics Holdings Inc. stock price fell by -3.95% on the last day (Tuesday, 16th Mar 2021) from $3.04 to $2.92.During the day the stock fluctuated 8.36% from a day low at $2.87 to a day high of $3.11. Entasis Therapeutics Holdings Inc. ETTX was a big mover last session, as the company saw its shares rise more than 5% on the day. Your browser is no longer supported. The move came on solid volume too with far more shares changing hands than in a normal session. Entasis Therapeutics was established in 2015 with start-up funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Entasis Therapeutics Holdings shares are less expensive than other comparable stocks. Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. Yahoo | July 13, 2020. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB. ETTX stock forecast Our latest prediction for Entasis Therapeutics Holdings Inc's stock price was made on the June 11, 2020 when the stock price was at 2.71$.. The company report on November 17, 2020 that Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium.. Get the hottest stocks to … If you had invested in Entasis Therapeutics Holdings stock at $10.66, your return over the last 2 years would have been -73.45%, for an annualized return of -48.48%. Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference, Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update, Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference, X-Biotix Therapeutics Joins Antimicrobials Working Group, Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019, Entasis Therapeutics Appoints David Meek as Chairman of the Board, Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019, Entasis Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference, Entasis Therapeutics Announces Initial ETX0282 Phase 1 Results, Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Microbe 2019. ENTASIS THERAPEUTICS HOLDINGS INC. : News, information and stories for ENTASIS THERAPEUTICS HOLDINGS INC. | Nasdaq: ETTX | Nasdaq See More Posts on {{symbol}} Message Board. Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections." Are Institutions Heavily Invested In Entasis Therapeutics Holdings Inc.'s (NASDAQ:ETTX) Shares? The price has been going up and down for this period, and there has been a 8.96% gain for the last 2 weeks. Since then, ETTX stock has decreased by 24.9% and is now trading at $3.10. Investor Relations Contacts James Salierno The Ruth Group (646) 536-7028 jsalierno@theruthgroup.com. Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Get the hottest stocks to trade every day before the market opens 100% free. Its products candidate includes Zoliflodacin, ETX0282CPDP, and NBP program. For all future releases Just for the upcoming release Level 1 Starter. Entasis Therapeutics Ltd PRIVATE Updated Mar 16, 2021 9:07 PM. Entasis Therapeutics Holdings Inc. stock price ended on $2.92 on Tuesday after losing 3.95% (Updated on March 16, 2021) Hold candidate since 2021-03-15 Loss -3.95% PDF . Only 27.55% of the stock of Entasis Therapeutics is held by institutions. It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. $67.09. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) concluded the trading at $2.46 on Friday, Mar 05, with a fall of -2.38% from its closing price on previous day. Entasis Therapeutics Holdings Inc () Stock Market info Recommendations: Buy or sell Entasis Therapeutics Holdings stock? It focuses on the discovery and development of novel antibacterial products. Stock Quote & Chart Stock Quote. Follow Entasis Therapeutics's earnings. As of Sep 29, 2020, the company held 9.9% of the shares, roughly 3.51 Million ETTX shares worth $7.16 Million. Entasis Therapeutics Holdings's share price could stay at $6.33 by Sep 9, 2021. During the day the stock fluctuated 8.36% from a day low at $2.87 to a day high of $3.11. Get the latest Entasis Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Entasis investment advice, charts, stats and more. InvestorsHub.com, Inc. The company report on November 17, 2020 that Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium.. Get the hottest stocks to … Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. Get today's Entasis Therapeutics Holdings Inc stock price and latest ETTX news as well as Entasis Therapeutics real-time stock quotes, technical analysis, full financials and more. Their average twelve-month price target is $6.71, predicting that the stock has a possible upside of 157.25%. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Entasis Therapeutics Holdings share forecasts, stock quote and buy / sell signals below.According to present data Entasis Therapeutics Holdings's ETTX shares and potentially its … The ratio of debt to operating expenses for Entasis Therapeutics Holdings Inc is higher than it is for about only 5.61% of US stocks. (See Ziopharm stock analysis on TipRanks)Entasis Therapeutics (ETTX)Last but not least we have Entasis Therapeutics, which develops molecules that could potentially address and overcome … — Ruben Tommasi, Chief Scientific Officer ©2021 Entasis Therapeutics Inc.